Furamag

Quick links to important sections

Furamag

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furamag

Quick Facts

Property Description
Active ingredient Furazidin (or Furazidin potassium)
Form Hard capsules (Capsules)
Pharmacological class Nitrofuran antibacterial agent
General therapeutic purpose Inhibits bacterial growth (bacteriostatic action)
Origin Synthetic organic compound

What is Furamag and What Class of Medicine is it?

Furamag is a prescription pharmaceutical entity classified as an antibacterial agent intended for systemic use. Its core active component is the International Nonproprietary Name (INN) substance Furazidin (or Furazidin potassium), a synthetic organic compound. The medication is definitively placed within the Nitrofuran derivatives group, which falls under the broader class of Other antibacterials. Furamag, as a brand, is clinically recognized for providing effective antibacterial action against common susceptible pathogens. This classification identifies it as a distinct anti-infective agent separate from traditional chemical classes, such as penicillins or macrolides. Nitrofuran derivatives have a specific role in combating susceptible bacterial pathogens through selective metabolic interference.


Composition, Form, and General Therapeutic Purpose

The medication is a single-ingredient product, consisting solely of the active molecule Furazidin and pharmaceutical excipients. Furamag is typically supplied for oral administration, predominantly in the form of hard capsules. The formulation often utilizes the potassium salt of Furazidin, which is distinguished by its enhanced solubility compared to other forms of the substance. The general therapeutic purpose of this nitrofuran agent is rooted in its ability to exert a bacteriostatic action. This means that instead of rapidly killing microorganisms, the medication works by interfering with their internal metabolic processes—thereby inhibiting their growth and multiplication. This action reduces the bacterial load, which assists the body's natural immune system in effectively managing a typical bacterial infection. The general effects of Furazidin involve the inhibition of bacterial proliferation.

What side effects are possible with Furamag?

Possible Side Effects and Safety Information

The safety profile of Furamag (containing Furazidin/Nitrofurantoin) is defined by officially documented adverse reactions categorized by frequency and the organ system affected.

Common and Expected Adverse Reactions

Gastrointestinal disturbances are among the most common adverse effects, including nausea, vomiting, diarrhea, and loss of appetite. Yellow or brown discoloration of the urine is an expected and harmless effect of the medication.

Serious Adverse Reactions

Although rare, some adverse reactions are clinically significant and require immediate attention, as documented in regulatory information. These serious risks typically involve specific organ systems:

  • Pulmonary Toxicity: Acute and chronic lung reactions (e.g., pneumonitis, pulmonary fibrosis) have been reported, sometimes associated with long-term use (six months or more).
  • Hepatotoxicity: Liver reactions, including chronic active hepatitis and hepatic necrosis, have occurred with both short- and long-term treatment.
  • Neuropathy: Peripheral neuropathy, involving sensory and motor nerve damage, can occur and may be irreversible, particularly in patients with pre-existing risk factors.
  • Blood Disorders: Rare reports of serious blood conditions, such as aplastic anemia and hemolytic anemia.

Safety Restrictions and Contraindications

Furamag is contraindicated (must not be used) in several specific patient groups to prevent serious harm, as explicitly stated in the regulatory labeling:

  • Patients with severe renal impairment (creatinine clearance less than 60 mL/minute).
  • Patients with a history of polyneuropathy or porphyria.
  • Infants under three months of age.
  • Pregnant women at term and breast-feeding mothers, due to the risk of hemolytic anemia in the neonate/infant.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section outlines the officially documented overdose information for Furamag (nitrofurantoin), strictly as defined in government regulatory sources. It does not provide clinical advice, standard dosing, or information on therapeutic uses.


Documented Manifestations and Serious Outcomes

Acute overdosage of nitrofurantoin is primarily characterized by gastrointestinal disturbances, including nausea and vomiting.

Of greater concern is the potential for serious nerve damage (peripheral neuropathy). Official documents note that high exposure, particularly in an overdose setting, increases the risk of developing or worsening peripheral neuropathy. This risk is notably heightened in patients with impaired renal function (e.g., Creatinine Clearance less than 60 mL/minute), as the body’s ability to excrete the drug is reduced.


Required Emergency Actions

No specific antidote for nitrofurantoin overdose is listed in official prescribing information.

Management is supportive and symptomatic.

Immediate medical help must be sought for any suspected overdose. The official instruction is to contact a Poison Control Center or emergency medical services immediately for management, which may include measures to enhance drug elimination, such as medically controlled fluid administration.

Therapeutic Uses of Furamag

What Furamag treats: main uses and benefits

Furamag is an antibacterial medication belonging to the nitrofuran group, primarily utilized for managing infections of the urinary tract and certain soft tissue structures. Unlike systemic antibiotics that distribute broadly throughout the body, the active components of this medication reach high concentrations specifically within the urinary system, making it a targeted option for localized infections.

Primary Indications

The medication is most commonly prescribed for the following conditions:

  • Acute Urinary Tract Infections: This includes sudden-onset infections of the bladder (cystitis) and the urethra (urethritis).
  • Recurrent Urinary Tract Infections: It is often used in cases where infections frequently return, helping to manage chronic irritation of the urinary lining.
  • Pyelonephritis: In certain clinical scenarios, it is used to treat infections that have affected the kidneys.
  • Prostatitis: It may be utilized for bacterial infections of the prostate gland when the causative pathogens are sensitive to nitrofurans.

Therapeutic Benefits

Furamag offers several specific clinical advantages in the treatment of bacterial infections:

  • Broad Antibacterial Spectrum: It is effective against a wide range of Gram-positive and Gram-negative bacteria, including many strains of Staphylococci and E. coli that may be resistant to other types of antibiotics.
  • Support of the Immune System: Research suggests that at therapeutic doses, nitrofurans can stimulate the phagocytic activity of white blood cells, potentially aiding the body’s natural defense mechanisms.
  • Low Resistance Development: Resistance to the active ingredient, furazidin, tends to develop more slowly compared to many other classes of antibiotics.
  • Lymphatic System Involvement: The medication is absorbed into the lymphatic system, which helps prevent the spread of bacteria through the lymph nodes during a localized infection.

Mechanism of Action

The medication works by inhibiting the biochemical processes within the bacterial cell. It disrupts the respiratory chain and the synthesis of DNA, which prevents the bacteria from multiplying and eventually leads to the destruction of the bacterial cell wall. This action helps to reduce inflammation and alleviate the symptoms associated with urinary tract discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information on Nitrofurantoin

Eligibility and Restrictions for Use

Who Can and Cannot Use Furamag?

Furamag (Furazidin) eligibility is strictly defined by regulatory authorities based on contraindications and patient characteristics.


Populations Explicitly Prohibited

Use is contraindicated for several specific groups. These include patients with a known hypersensitivity to Furazidin or any other nitrofuran derivative, and individuals with pre-existing conditions such as polyneuropathy (of any origin) or Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Absolute contraindications also apply to individuals with severe renal impairment (typically defined by a significantly reduced creatinine clearance) and pregnant women at term (late stage pregnancy).


Age and Conditional Use

The medication is contraindicated in children under the age of 3 years. For pregnant women not at term and women who are breastfeeding, use is generally not recommended.

Patients with mild to moderate renal impairment, diabetes mellitus, or Vitamin B deficiency are permitted to use Furamag, but the official labeling mandates special caution due to increased risks of toxicity, such as peripheral neuropathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Furamag (Furazidin potassium) is officially documented by regulatory authorities, focusing on combinations that affect its systemic exposure, increase toxicity, or produce pharmacodynamic effects.

Documented Pharmacodynamic and Exposure Interactions

Co-administration with Sulphanilamides can negatively affect haemapoiesis. Conversely, combining Furamag with certain antibiotics, specifically penicillins and cephalosporins, is documented to result in a significantly enhanced antibacterial activity. Uricosurics, such as probenecid and sulfinpyrazone, may increase a toxic effect when taken concurrently.

Physiological and Substance-Specific Restrictions

The medicine's activity is sensitive to changes in urine pH. Agents that alkalify the urine decrease the nitrofuran agent’s activity, whereas agents that acidify the urine, including Ascorbic acid and Calcium chloride, increase the effect but may also increase the risk of toxic effects. The regulatory information notes that the presence of food promotes the medicine absorption.

Official Combination Constraints

The label defines strong constraints for certain combinations: co-administration with alcoholic beverages must be avoided due to the potential for unfavorable side effects. Concomitant use with quinolones (e.g., nalidixic acid) should be avoided. Additionally, there is a risk of adverse effects being exacerbated in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Mechanism of Action

Targeted Prodrug Activation and Specificity

The antibacterial action begins when the inactive Furazidin molecule enters the bacterial cell and is converted into highly potent, reactive intermediates. This critical activation step is performed exclusively by specific bacterial nitroreductase enzymes (flavoproteins), ensuring the formation of active compounds is contingent upon the specific enzymatic machinery within the pathogen. This activation mechanism contributes to the selectivity of its action against the target microorganism.

Simultaneous Multi-Target Damage

Once active, these intermediates act as broad-spectrum cellular toxins, causing simultaneous damage to multiple essential bacterial structures. The drug inactivates bacterial DNA, impairs crucial ribosomal proteins necessary for protein synthesis, and disrupts key metabolic enzymes required for energy production. This comprehensive assault leads to rapid, mass failure of growth and division, which is the mechanism underpinning its bacteriostatic effect (inhibition of proliferation).

️ Mechanism Limitations

The efficacy of the drug's mechanism can be challenged by adaptive changes in bacteria. Limitations arise when mutations occur in the genes encoding the activating nitroreductase enzymes, reducing the formation of the active drug. Furthermore, bacterial efflux pumps can actively expel the drug, preventing it from reaching the necessary intracellular concentration to initiate the damage cascade, leading to reduced intracellular accumulation and subsequent lower intensity of the damage cascade.

Dosage and Administration Information

Instruction Map: How to use Furamag — Official Administration Guidelines

Furamag (Furazidin potassium) is administered exclusively via the oral route in the form of hard capsules, which are available in 25 mg and 50 mg strengths. The medicine must be taken after meals to aid absorption and should be swallowed unbroken with a sufficient quantity of liquid.


Administration Scope

Instruction Detail
Route of administration Oral (via the gastrointestinal tract).
Dosing schedule (Adult Treatment) 50 mg to 100 mg per dose, with a maximum total daily intake of 300 mg.
Dosing schedule (Adult Prophylaxis) 50 mg per dose.
Timing in relation to meals Must be taken after meals.

Frequency, Duration, and Population Rules

The frequency of use is determined by the treatment goal. Acute administration is typically scheduled three times daily (TID). Prophylactic or long-term maintenance use is usually administered once daily, often before bedtime.

Instruction Detail
Frequency pattern Acute: Three times daily (TID). Prophylaxis: Once daily.
Age-group administration rules Pediatric dosing is calculated on a weight-based basis ( mg/kg) per day, divided into 2 or 3 doses, until the patient reaches the weight threshold for the standard adult regimen.
Course Duration / Cycle Acute Course: 7 to 10 days. Interval: 10 to 15 days must pass before a repeat course is initiated.

The adherence to these parameters ensures the medicine is used consistently with the established dosing and administration framework.

Recent Clinical Evidence

Furamag (Furazidin): Recent Clinical Evidence

The antimicrobial drug Furamag, which contains the active substance furazidin (a nitrofuran derivative), has been investigated primarily for the treatment of uncomplicated urinary tract infections (UTIs), including acute and recurrent cystitis.

Clinical Efficacy and Bacteriological Findings

Studies have assessed the effectiveness of furazidin in both clinical and bacteriological terms. Research has focused on its activity against common uropathogens, such as Escherichia coli and Enterococcus spp., which are frequent causes of UTIs.

Comparative trials have been conducted to evaluate furazidin against other antimicrobial agents used for UTIs. For example, in one prospective controlled study involving women with acute uncomplicated cystitis, the bacteriological eradication rates were observed to be higher with furazidin than with certain fluoroquinolone antibiotics.

Additionally, research has explored the use of furazidin in combination therapy for more complex cases, such as nosocomial (hospital-acquired) UTIs. These studies have examined whether the addition of furazidin to cephalosporin therapy (a type of broad-spectrum antibiotic) may contribute to improved pathogen eradication rates in these difficult-to-treat infections.

Study Focus Key Observation Study Type/Scope
Uncomplicated Cystitis Higher pathogen eradication rates observed compared to certain fluoroquinolones. Prospective Controlled Trial (Women)
Nosocomial UTIs Combination therapy with furazidin was associated with higher bacteriological eradication compared to monotherapy. Randomized Comparative Trial (Adults)

Pharmacokinetics and Study Demographics

Clinical pharmacology studies have characterized the drug's absorption profile, including an assessment of how food intake may influence its bioavailability. The drug's safety and effectiveness have been evaluated across various patient populations, with a particular focus on female adults with acute or recurrent cystitis. Studies have also been conducted in pediatric populations and in patients with chronic renal conditions.

Frequently Asked Questions (FAQ)

Common questions about Furamag (FAQ)

Q: How quickly does Furamag start working for a UTI?

A: Studies and official information indicate that the antibacterial action begins shortly after administration. Clinical data suggests that a positive clinical response is typically associated with a reduction in the body's inflammatory response within the first few days of treatment.

Q: Does taking Furamag with food reduce side effects?

A: Furamag is required to be taken after meals to help improve the medicine's absorption into the body. The requirement to take it with food may also help mitigate common gastrointestinal side effects, such as nausea and general stomach upset, which are frequently reported with this type of medicine.

Q: Can people with kidney problems take Furamag?

A: The use of Furamag is strictly contraindicated in patients who have severe renal impairment (a specific level of poor kidney function). Official guidelines require special caution for use in patients with mild or moderate kidney impairment due to a potential increase in the risk of toxicity.

Q: Are there any long-term side effects associated with Furamag use?

A: Regulatory documents report serious risks associated with prolonged use of Furamag, which is typically defined as six months or more. These potential issues include lung toxicity and liver problems. The typical course duration for an acute infection is short and falls outside the period defined as long-term use.

Q: Can Furamag interact with supplements like vitamin C or cranberry?

A: Official information states that agents which acidify the urine, such as Ascorbic acid (a form of Vitamin C), can influence the way the medicine works. This can increase both the intended effect and the risk of toxic effects. Due to the effect on the medicine's activity, patients are typically advised to discuss the use of such supplements with a healthcare provider.

Q: What foods or drinks should I avoid while on Furamag?

A: According to the official product information, co-administration with alcoholic beverages must be strictly avoided. This restriction is imposed due to the potential for unfavorable side effects when the two substances are combined.

Q: Is Furamag a safe option during pregnancy?

A: Furamag is explicitly contraindicated for use in pregnant women at term (during the late stage of pregnancy). For women who are not yet at term, use of the medicine is generally not recommended due to the risk of harm to the neonate, as outlined in official warnings.

Q: Can I take Furamag if I'm allergic to penicillin?

A: The medicine is contraindicated only for those with a known allergy (hypersensitivity) to Furazidin or any other nitrofuran derivative. Regulatory information does not indicate a specific cross-allergy warning with penicillin, and has noted that combining Furamag with penicillin may enhance its antibacterial activity.

Q: Does Furamag make you tired or dizzy?

A: Official product information suggests that adverse effects related to the nervous system may occur in some patients. These can include effects such as dizziness or somnolence (drowsiness). If these effects occur, they may affect the ability to safely drive or operate machinery, and caution is warranted.

Q: What should I do if I get a rash while taking Furamag?

A: Any serious adverse reaction, including severe dermatological issues such as a rash, requires immediate medical attention. If any unexpected or serious adverse reaction is observed, immediate consultation with a healthcare professional is advised.

Q: Is Furamag the same as Furagin?

A: Furamag is a brand name for the active substance Furazidin. Furazidin is the chemical compound that provides the therapeutic effect. The term Furagin is an alternative name used for this same active substance in certain contexts or regulatory texts.

Q: Is Furamag effective against all types of bacteria that cause UTIs?

A: Furamag works only against certain susceptible strains of bacteria that cause urinary tract infections. Regulatory documents specifically indicate its activity against common uropathogens, such as Escherichia coli and Enterococcus spp., and not all types of bacteria.

Q: Can taking Furamag upset the balance of 'good' bacteria in the gut?

A: Official product information includes gastrointestinal disturbances as common side effects. These can include nausea, vomiting, or diarrhea, which are adverse effects that affect the digestive tract.

Q: Is it okay to drive while taking Furamag?

A: The medication may cause adverse reactions that can affect the central nervous system, such as dizziness or somnolence (drowsiness). If these effects occur, they may impair the ability to drive or operate machinery, and caution may be required.

Q: Are there any reported cases of liver issues with Furamag?

A: Regulatory documents confirm that serious liver reactions have been reported in association with the use of Furamag. These include conditions such as chronic active hepatitis and hepatic necrosis, which can occur with both short-term and long-term use.

Q: What should I expect the first few hours after taking Furamag?

A: Common and expected side effects, such as gastrointestinal disturbances, including nausea and vomiting, may begin to occur relatively soon after taking a dose. Taking the medicine with food, as instructed, may help mitigate the intensity of these common, immediate effects.

How should Furamag be stored and disposed of?

How to Store and Dispose of Furamag?

To ensure product stability and safety, Furamag (furazidin) must be stored under specific conditions.

Requirement Official Regulatory Statement
Temperature Do not store above 25 C.
Protection Store in the original package to protect from light and moisture.
Child Safety Keep out of the sight and reach of children.
Handling Do not use Furamag after the expiry date stated on the package.

For disposal, never throw away Furamag capsules via wastewater or household waste. Proper disposal is necessary to protect the environment. Ask your pharmacist for guidance on how to safely and responsibly discard medicines you no longer need.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furamag found in:

A-Z Index: